So there are a number of trials that are currently in progress that involve developsip and I and I um. Uh, in the future, I, I, I see the role of Develoed being expanded and being more refined, and so what I mean by that is, um, we will have more data, um, that we can utilize to, to evaluate in which subtype is developed most effective and where it should be used. Um, and in addition, I think uh we will be able to have data um to use Develosip in Various different settings, not just in, you know, the first line treatment with Chop, um, or in the relapse refractory setting as monotherapy or with Romodapsin, but it may be combined with other agents. Um, in the first line and relapse refractory setting, it may be used without chemotherapy, um, in the future, it may be used, um, you know, after first line treatment or after aloe, uh, or. Um, to attempt, uh, to control the disease. Um, so that, that's where I see develops. I do see it playing an important role, uh, in the, in the, uh, future treatment landscape in PTCL.
Presenter
